18-Jun-2026
No press releases found.
JPMorgan bankers say Big Pharma M&A still outpaces biotech IPOs: report
Seeking Alpha News (Tue, 16-Jun 4:16 AM ET)
The SPDR S&P Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Pharmaceuticals Select Industry Index (the Index ).The S&P Pharmaceuticals Select Industry Index (the Index ) represents the pharmaceuticals segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the Pharmaceuticals sub-industry. The Index is one of twenty-one (21) of the S&P Select Industry Indices (the Select Industry Indices ), each designed to measure the performance of a narrow sub-industry or group of sub-industries determined based on the Global Industry Classification Standard ( GICS ).
State Street SPDR S&P Pharmaceuticals ETF trades on the ARCA stock market under the symbol XPH.
As of June 18, 2026, XPH stock price climbed to $61.04 with 33,980 million shares trading.
XPH has a beta of 0.97, meaning it tends to be less sensitive to market movements. XPH has a correlation of 0.34 to the broad based SPY ETF.
XPH has a market cap of $366.26 million. This is considered a Small Cap stock.
In the last 3 years, XPH traded as high as $61.46 and as low as $34.67.
XPH has outperformed the market in the last year with a price return of +50.1% while the SPY ETF gained +26.9%. XPH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.1% and +5.4%, respectively, while the SPY returned +13.5% and -1.1%, respectively.
XPH support price is $59.69 and resistance is $61.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XPH shares will trade within this expected range on the day.